Law360, New York (January 04, 2008, 12:00 AM ET) -- Despite months of plaintiffs' lobbying, the federal judge overseeing the Fosamax product liability litigation against pharmaceutical giant Merck & Co. has declined to grant class status to patients who have not yet developed a painful jaw condition allegedly linked to the osteoporosis medication.
On Thursday, Judge John Keenan of the U.S. District Court for the Southern District of New York batted down a motion by patients in Florida, Pennsylvania and Louisiana, maintaining that a class action would not be the proper way to pursue its bid...
Merck Scores As Judge Spurns New Fosamax Class
To view the full article, take a free trial now.
